Update on the adverse effects of clozapine: Focus on myocarditis

Current Drug Safety

Volumn 7, Issue 1, 2012, Pages 55-62

  de Berardis, Domenico ^a,b   Serroni, Nicola ^a   Campanella, Daniela ^a   Olivieri, Luigi ^a   Ferri, Francesca ^a   Carano, Alessandro ^b,c   Cavuto, Marilde ^d   Martinotti, Giovanni ^e   Cicconetti, Alessandra ^f   Piersanti, Monica ^a   Moschetta, Francesco Saverio ^a   Di Giannantonio, Massimo ^b  

^a G Mazzini Hospital   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Psychiatric Service of Diagnosis and Treatment   (Italy)

^d IASM   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f Hospital S Liberatore   (Italy)

Author keywords

Cardiomyopathy schizophrenia; Clozapine; Heart failure; Myocarditis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMITRIPTYLINE; BETA LACTAM ANTIBIOTIC; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CISAPRIDE; CLOZAPINE; CREATINE KINASE; CREATINE KINASE MB; CYCLOPHOSPHAMIDE; DESIPRAMINE; FLUVOXAMINE; IMIPRAMINE; LEVOTHYROXINE SODIUM; LITHIUM; LIVER ENZYME; PHENOTHIAZINE; RANITIDINE; SERTRALINE; SULFONAMIDE; TRIACYLGLYCEROL; TROPONIN I; TROPONIN T; NEUROLEPTIC AGENT;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; CARDIOGENIC SHOCK; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; CLINICAL PROTOCOL; COMORBIDITY; CONFUSION; CONGESTIVE CARDIOMYOPATHY; CONSTIPATION; COUGHING; CYANOSIS; DELIRIUM; DIAGNOSTIC ACCURACY; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYAPNEA; DYSARTHRIA; DYSURIA; ECG ABNORMALITY; EOSINOPHILIA; EPIDEMIOLOGICAL DATA; ERYTHROCYTE SEDIMENTATION RATE; EXERCISE TOLERANCE; FAINTNESS; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART EDEMA; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FILLING; HEART MUSCLE BIOPSY; HEART PALPITATION; HEART RATE; HEART RIGHT VENTRICLE SYSTOLIC DYSFUNCTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPEREOSINOPHILIA; HYPERSALIVATION; HYPERTHERMIA; HYPOTENSION; IMPOTENCE; INFLAMMATORY INFILTRATE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOCYTOSIS; LOW DRUG DOSE; LUNG EDEMA; MALAISE; MENTAL INSTABILITY; MOOD DISORDER; MYALGIA; MYOCARDITIS; NAUSEA; NEUTROPHILIA; NOSE OBSTRUCTION; ORTHOPNEA; ORTHOSTATIC HYPOTENSION; PAROXYSMAL DYSPNEA; PATHOPHYSIOLOGY; PATIENT MONITORING; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PR INTERVAL; PRIORITY JOURNAL; PSYCHOSIS; PULMONARY VENOUS CONGESTION; Q WAVE; RASH; REBOUND; RISK BENEFIT ANALYSIS; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SEIZURE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SINUS TACHYCARDIA; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SYSTOLIC DYSFUNCTION; T WAVE; TACHYCARDIA; TARDIVE DYSKINESIA; THORAX PAIN; THROAT IRRITATION; THROMBOEMBOLISM; URINE INCONTINENCE; URINE RETENTION; VENOUS CONGESTION; VOMITING; WEIGHT GAIN; CHEMICALLY INDUCED DISORDER; DRUG LABELING; FOOD AND DRUG ADMINISTRATION; REVIEW; UNITED STATES;

ANTIPSYCHOTIC AGENTS; CARDIOMYOPATHIES; CLOZAPINE; DRUG LABELING; HUMANS; MYOCARDITIS; SCHIZOPHRENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867640817     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488612800492681     Document Type: Article

References (93)

1. van Os J, Kapur S. Schizophrenia. Lancet 2009 22; 374(9690): 635-45.
2. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002; 47(9): 833-43.
3. Freedman R. Schizophrenia. N Engl J Med 2003; 349(18): 1738-49.
4. Elkis H. Treatment-resistant schizophrenia. Psychiatr Clin North Am 2007; 30(3): 511-3.
5. Marasco V, De Berardis D, Serroni N, et al. Alexithymia and suicide risk among patients with schizophrenia: preliminary findings of a cross-sectional study. Riv Psichiatr 2011; 46(1): 31-7
6. Kane J, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment resistant schizophrenia. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45(9): 789-96
7. Buckley PF, Shendarkar N. Treatment-refractory schizophrenia. Curr Opin Psychiatry 2005; 18(2): 165-73.
8. Van Sant SP, Buckley PF. Pharmacotherapy for treatmentrefractory schizophrenia. Expert Opin Pharmacother 2011; 12(3): 411-34.
9. Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiatr Pract 2002; 8(4): 205-15.
10. Lindenmayer JP, Czobor P, Volavka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004; 65(4): 551-6.
11. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209-2.
12. Kane JM. A user' guide to clozapine. Acta Psychiatr Scand 2011; 123(6): 407-8.
13. Agid O, Foussias G, Singh S, Remington G. Where to position clozapine: re-examining the evidence. Can J Psychiatry 2010; 55(10): 677-84.
14. Hirsch SR, Puri BK. Clozapine: progress in treating refractory schizophrenia. BMJ 1993; 306(6890): 1427-8.
15. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21(4): 579-91.
16. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55(Suppl B): 47-52.
17. Kang X, Simpson GM. Clozapine: more side effects but still the best antipsychotic. J Clin Psychiatry 2010; 71(8): 982-3.
18. Volavka J, Citrome L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int J Clin Pract 2008; 62(8): 1237-45.
19. Agid O, Foussias G, Singh S, Remington G. Where to position clozapine: re-examining the evidence. Can J Psychiatry 2010; 55(10): 677-84.
20. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011; 123(6): 411-22.
21. Schulte PFJ. The risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006; 40(4): 683-8.
22. Drew LRH. Controls on clozapine must be reviewed. Aust N Z J Psychiatry 2010; 44(5): 490.
23. Wagstaff AJ, Bryson HM. Clozapine? CNS Drugs 1995; 4(5): 370-400.
24. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res 2009; 110(1-3): 95-102.
25. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003; 15(1): 33-48.
26. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010; 23(6): 574-81
27. Pieroni M, Cavallaro R, Chimenti C, Smeraldi E, Frustaci A. Clozapine-Related Hypersensitivity Myocarditis. Chest 2004; 126(5): 1703-5.
28. Makhoul B, Hochberg I, Rispler S, Azzam ZS. Dilated cardiomyopathy: an unusual complication of clozapine therapy. Nat Clin Pract Cardiovasc Med 2008; 5(9): 566-70.
29. Leo RJ, Kreeger JL, Kim KY. Cardiomyopathy associated with clozapine. Ann Pharmacother 1996; 30(6): 603-5.
30. Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother 1997; 31(2): 168-70.
31. Varma S, Achan K. Dysrhythmia associated with clozapine. Aust N Z J Psychiatry 1999; 33(1): 118-119.
32. Kakar P, Millar-Craig M, Kamaruddin H, Burn S, Loganathan S. Clozapine induced myocarditis: a rare but fatal complication. Int J Cardiol 2006; 112(2): e5-6.
33. Rostagno C, Domenichetti S, Pastorelli F, Gensini GF. Clozapine associated cardiomyopathy: a cluster of 3 cases. Intern Emerg Med 2011; 6(3): 281-3.
34. Roh S, Ahn DH, Nam JH, Yang BH, Lee BH, Kim YS. Cardiomyopathy associated with clozapine. Exp Clin Psychopharmacol 2006; 14(1): 94-8.
35. Ronaldson KJ, Taylor AJ, Fitzgerald PB, Topliss DJ, Elsik M, McNeil JJ. Diagnostic characteristics of clozapine-related myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry 2010; 71(8): 976-81.
36. Merrill DB, Ahmari SE, Bradford JM, Lieberman JA. Myocarditis during clozapine treatment. Am J Psychiatry 2006; 163(2): 204-8.
37. Vesterby A, Pedersen JH, Kaempe B, Thomsen NJ. Sudden death during treatment with clozapine (Leponex). Ugeskr Laeger 1980; 142(3): 170-1.
38. Bandelow B, Degner D, Kreusch U, Rüther E. Myocarditis under therapy with clozapine. Schizophr Res 1995; 17(3): 293-4.
39. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine in the United States. N Engl J Med 2001; 345(3): 224-5.
40. Rostagno C, Di Norscia G, Placidi GF, Gensini GF. Beta-blocker and angiotensin-converting enzyme inhibitor may limit certain cardiac adverse effects of clozapine. Gen Hosp Psychiatry 2008; 30(3): 280-3
41. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. Clinical course and analysis of ten fatal cases of clozapine-related myocarditis and comparison with 66 surviving cases. Schizophr Res 2011; 128(1-3): 161-5
42. Fineschi V, Neri M, Riezzo I, Turillazzi E. Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. Int J Legal Med 2004; 118(5): 307-9.
43. Warner B, Alphs L, Schaedelin J, Koestler T. Clozapine and sudden death. Lancet 2000; 355: 842
44. Association of Clozaril (clozapine) with cardiovascular toxicity [Dear Healthcare Professional letter]. Dorval (QC): Novartis Pharmaceuticals Canada Inc.; 2002 Jan 14. Available: http: //www.hc-sc.gc.ca/dhp-mps/medeff/advisoriesavis/ prof/_2002/clozaril_hpc-cps-eng.php (accessed 2011 Jun 29).
45. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354(9193): 1841-5.
46. Committee on Safety of Medicines. Myocarditis with antipsychotics: recent cases with clozapine (Clozaril). Curr Prob Pharmacovigil 1993; 19: 9-10.
47. Grohmann R, Rüther E, Engel R, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with AMSP Drug Safety Program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry 1999; 32(1): 21-8.
48. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8(6): 671-7.
49. Haas SJ, Hill R, Krum H et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30(1): 47-57.
50. Reinders J, Parsonage W, Lange D, Potter JM, Plever S. Clozapinerelated myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004; 38(11-12): 915-22.
51. Kay SE, Doery J, Sholl D. Clozapine associated pericarditis and elevated troponin I. Aust N Z J Psychiatry 2002; 36(1): 143-4.
52. Murko A, Clarke S, Black DW. Clozapine and pericarditis with pericardial effusion. Am J Psychiatry 2002; 159(3): 494.
53. Thanasan S, Rusdi AR. A Case of Suspected Clozapine Related Myocarditis. Mal J Psychiatry 2009: 18(1): 1-4.
54. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21(4): 382-8.
55. Marder SR, Van PT. Who should receive clozapine? Arch Gen Psychiatry 1988; 45(9): 865-7
56. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-related myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45(6): 458-65.
57. Lang UE, Willbring M, von Golitschek R, Schmeisser A, Matschke K, Malte Tugtekin S. Clozapine-related myocarditis after long-term treatment: case presentation and clinical perspectives. J Psychopharmacol 2008; 22(5): 576-80
58. Devarajan S, Kutcher SP, Dursun SM. Clozapine and sudden death. Lancet 2000; 355(9206): 841.
59. Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 2008; 121(1283): 68-75.
60. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322(7296): 1207-9.
61. Varambally S, Howpage P. Acute myocarditis associated with clozapine. Australas Psychiatry 2007; 15(4): 343-6
62. Hoehns JD, Fouts MM, Kelly MW, Tu KB. Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother 2001; 35(7-8): 862-6.
63. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011; 123(6): 411-22.
64. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25(1): 32-41.
65. Pui-yin Chung J, Shiu-yin Chong C, Chung KF, Lai-wah Dunn E, Wai-nang Tang O, Chan WF. The incidence and characteristics of clozapine-related fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53(12): 857-62.
66. Tham JC, Dickson RA. Clozapine-related fevers and 1-year clozapine discontinuation rate. J Clin Psychiatry 2002; 63(10): 880-4.
67. Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation 2006; 113(6): 876-90.
68. Razminia M, Salem Y, Devaki S, Shah N, Khosla S. Clozapine related myopericarditis: early recognition improves clinical outcome. Am J Ther 2006; 13(3): 274-6.
69. Annamraju S, Sheitman B, Saik S, Stephenson A. Early recognition of clozapine-related myocarditis. J Clin Psychopharmacol 2007; 27(5): 479-83.
70. Adamaszek M, Olbrich S, Hegerl U, Schönknecht P. The risk for myocarditis of clozapine and other atypical antipsychotics: case report and study of the literature. Psychiatr Prax 2011; 38(4): 201-3.
71. Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ 2002; 166(9): 1185-6.
72. Berk M, Fitzsimons J, Lambert T, et al. Monitoring the safe use of clozapine: a consensus view from Victoria, Australia. CNS Drugs 2007; 21(2): 117-27
73. Cooper LT Jr. Myocarditis. N Engl J Med 2009; 360(15): 1526-38.
74. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet 2012; 379: 736-47.
75. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997; 95(6): 1686-744.
76. Ariyarajah V, Shaikh N, Garber PJ, Kirkpatrick I, McGregor R, Jassal DS. Cardiovascular magnetic resonance in mild to moderate clozapine-related myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities? J Magn Reson Imaging 2010; 31(6): 1473-6.
77. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation 2006; 113(4): 593-5.
78. Fineschi V, Neri M, Riezzo I, Turillazzi E. Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment. Int J. Legal Med 2004; 118(5): 307-9.
79. Gleich GJ, Jacoby DB, Fryer AD. Eosinophil-associated inflammation in bronchial asthma: a connection to the nervous system. Int Arch Allergy Immunol 1995; 107(1-3): 205-7.
80. Elman I, Goldstein DS, Eisenhofer G, et al. Mechanism of peripheral noradrenergic stimulation by clozapine. Neuropsychopharmacology 1999; 20(1): 29-34.
81. Lychkova AE. A model of myocarditis. Bull Exp Biol Med 2002; 134(1): 98-9.
82. Layland JJ, Liew D, Prior DL. Clozapine-related cardiotoxicity: a clinical update. Med J Aust 2009; 190(4): 190-2.
83. Novo G, Assennato P, Augugliaro S, et al. Midventricular dyskinesia during clozapine treatment? J Cardiovasc Med 2010; 11(8): 619-21.
84. Kamphuis H, Arends J, Timmerman L, van Marle J, Kappert J. Myocarditis and cardiomyopathy: underestimated complications resulting from clozapine therapy. Tijdschr Psychiatr 2010; 52(4): 223-33
85. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010; 52(4): 274-88.
86. Reid P. Clozapine rechallenge after myocarditis. Aust N Z J Psychiatry 2001; 35(2): 249.
87. Jayathilake I, Singh AK. Clozapine rechallenge after myocarditis. Australas Psychiatry 2009; 17(5): 421-2.
88. Rosenfeld AJ, Gibbs T, Ivie R, Clarke L, Merrill DB. Successful clozapine retrial after suspected myocarditis. Am J Psychiatry 2010; 167(3): 350-1.
89. Bray A, Reid R. Successful clozapine rechallenge after acute myocarditis. Aust N Z J Psychiatry 2011; 45(1): 90.
90. Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012; 134: 180-6.
91. Pastor CA, Mehta M. Masked clozapine-induced cardiomyopathy. J Am Board Fam Med 2008; 21(1): 70-4.
92. Grgas M, Washburn CF Jr, Caley CF. Clozapine-related myocarditis: 2 case reports. J Clin Psychopharmacol 2010; 30(1): 91-2.
93. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010; 24(7): 965-71.